Precision Medicine Test for Psoriasis Predicts Response Rate to Biologics

A poster presented at the San Diego Dermatology Symposium dove into the results of a study on the use of Mindera Health’s Mind.Px program in physician decision-making and patient outcomes.¹ Mind.Px is a machine learning-based test that can help determine a patient’s response to a biologic treatment with a positive predictive value of greater than 91%.²

It is a painless, minimally invasive test that is placed on the patient’s skin for 5 minutes. The ribonucleic acid (RNA) gathered from the patch biopsy is then used to evaluate more than 7,000 biomarkers to determine the patient’s best treatment option through biologic therapy.

A past survey found that³:

1. 100% of physicians would use Mind.Px if it were incorporated into the prior authorization process;
2. 98% would use Mind.Px if it were available to them;
3. 98% believe that Mind.Px would improve patient outcomes; and
4. 93% would utilize Mind.Px predictive results to determine first line therapy even if this differed from their initial clinical choice.

The STAMP study⁴ was a 16-week 1:1 randomized study screened 200 patients and 51 were enrolled into the trial from 14 different testing sites. To be included patients had to have a lesion greater than or equal to 2 cm in diameter and have both a Psoriasis Area and Severity Index (PASI) score of 10 or more and a Physician Global Assessment (PGA) of 3 or more. Twenty-six patients were randomized into the test informed arm vs 25 in the treatment as usual (TAU) arm. The physicians were provided test results prior to biologic selection in the test informed arm.

In the primary findings from this study, it was found that 91.7% of physicians used the biologic that the Mind.Px program recommended in the test informed arm. The researchers believe that it will be important to continue to monitor the number of physicians who do follow what the platform recommends.

They will keep a close eye on drivers in those cases where Mind.Px informed physicians are not concordant with the test result and what causes this decision whether it be insurance, physician choice, or patient preference. As of now, the number of physicians who do not follow recommendation remain low and generalized conclusions as to why non-concordance occurs cannot be made.

Reference

1. Strober, BE. Kunder, A. Boyce, C. Dermatologist Concordance with a Precision Medicine Test for the Selection of Psoriasis Biologic Treatment. Presented at: 2022 San Diego Dermatology Symposium, March 11-13, 2022, San Diego, California.
2. Bagel J, Wang Y, Paul Montgomery III, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5
3. Strober B, Pariser D, Deren-Lewis A, Dickerson TJ, Lebwohl M, Menter A. A survey of community dermatologists reveals the unnecessary impact of trial-and-error behavior on the psoriasis biologic treatment paradigm. Dermatol Ther (Heidelb). 2021;11(5):1851-1860. doi:10.1007/s13555-021-00573-1
4. Mindera Health. An Exploratory, Multicenter, Observational Study to Examine Rna Biomarkers of Psoriasis Subjects through the Application of the Mindera Kit Part 2 (STAMP-2). clinicaltrials.gov; 2021. Accessed May 23, 2022. https://clinicaltrials.gov/ct2/show/NCT04904315